Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the fro ...

GF-CART01 has shown positive clinical trial data in Taiwan. Credit: ultramansk / Shutterstock.com. Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated ...

Sling is racing to market the first oral IGF-1R blocker, which would likely provide competition to Amgen’s Tepezza.

QurCan uses its TERP platform to facilitate non-viral delivery of genetic medicines. Credit: MrWinn / Shutterstock.com. Eli Lilly and Company and QurCan Therapeutics have signed an exclusive research ...

Definium Therapeutics plans to submit an NDA for LSD-based psychedelic, DT120 in generalised anxiety disorder (GAD) during H1 2027.

Cheplapharm will acquire production sites in Hungary, Singapore and France. Credit: Gorodenkoff / Shutterstock.com. Cheplapharm has entered a strategic partnership to take over a portfolio of 20 ...

While Novo Nordisk will remain its legal name, the change means Novo will be its front-facing identifier alongside its trusted Apis bull. Credit: Novo. When Mike Doustdar joined Novo Nordisk as CEO, ...

Share prices tumbled last week after a key asset from Novartis’ $12bn Avidity deal fumbled in a Phase III trial.

Cell and gene therapies are fuelling new possibilities for rare diseases, turning a field defined by unmet need into one of the industry’s most dynamic areas of innovation.

Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS.

At ERS 2026, investigators reported their findings from their review of the Oxford Asthma Attack Risk Scale Meta-Analysis (ORACLE2).

Biotechs and investors are increasingly altering their strategies amid changes in the development and commercial landscape.